Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated thymosin alpha 1
- Development stage
- Unknown
- Lead developer
- Jiangsu Hengrui Medicine
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
Pegylated thymosin alpha 1 (SHR0401) is a long-acting immunomodulatory peptide developed by Jiangsu Hengrui Medicine for the treatment of chronic hepatitis B (CHB). It is a modified version of thymosin alpha 1 (thymalfasin), a synthetic 28-amino acid peptide identical to the natural peptide found in the thymus. By conjugating the peptide to a polyethylene glycol (PEG) moiety, the drug's half-life is significantly extended, allowing for less frequent dosing compared to the standard twice-weekly regimen of non-pegylated thymalfasin. The mechanism of action involves the activation of Toll-like receptors, specifically TLR9 and TLR2, on myeloid and plasmacytoid dendritic cells. This activation triggers the maturation of T-cells and the production of Th1-type cytokines, such as interferon-gamma and interleukin-2, thereby enhancing the host's cellular immune response against the hepatitis B virus. SHR0401 is currently being investigated in clinical trials to evaluate its efficacy in achieving HBsAg loss and functional cure in patients with chronic hepatitis B.
- Other names
- pegylated thymalfasinPEG-Tα1PEG-thymosin alpha 1
02
Targets
TLR9 (Toll-like receptor 9)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on pegylated thymosin alpha 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated thymosin alpha 1.